VRDN

Latest SEC Filings & News for VRDN

2 most recent filings and news items mentioning VRDN. Updated every 60 seconds.

Get this data via API — free tier: 10,000 calls/day
curl "https://api.brieftape.com/v1/tickers/VRDN/news?limit=20"

Pull VRDN filings straight into your trading bot, model, or app.

Get an API key — free tier: 10,000 calls/day
Trading IdeasJun 29, 2026Neutral

Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease

Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease

View filing at SEC.gov →
RegulatoryJun 26, 2026Positive

Viridian Therapeutics wins FDA approval for lumvoa.

Viridian Therapeutics announced the FDA approval and immediate launch of Lumvoa for thyroid eye disease. This makes Lumvoa the first approved treatment for both active and chronic TED and represents a major milestone for the company.

View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.